Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Clarity Pharmaceuticals Ltd. ( (AU:CU6) ) just unveiled an announcement.
Clarity Pharmaceuticals has signed a supply agreement with The University of Queensland’s Australian Institute for Bioengineering and Nanotechnology for copper-64, which will support multiple clinical trials and pre-clinical programs. This agreement enhances Clarity’s capacity to provide innovative diagnostic options for prostate cancer and supports the development of theranostic programs, reflecting the company’s commitment to advancing cancer treatment and strengthening its collaborations within the Australian scientific community.
More about Clarity Pharmaceuticals Ltd.
Clarity Pharmaceuticals Ltd. is a clinical-stage radiopharmaceutical company focused on developing next-generation products to improve cancer treatment outcomes for both children and adults. The company is engaged in creating advanced diagnostic and therapeutic agents, particularly for prostate cancer, and is actively involved in research and development collaborations, including participation in the Australian Research Council Hub for Advanced Manufacture of Targeted Radiopharmaceuticals.
YTD Price Performance: -14.63%
Average Trading Volume: 1,689,817
Technical Sentiment Consensus Rating: Buy
Current Market Cap: A$1.14B
For detailed information about CU6 stock, go to TipRanks’ Stock Analysis page.